|
rs1414334
|
|
|
0.050 |
GeneticVariation |
BEFREE |
An association has been found between the C allele of the rs1414334 polymorphism in the HTR2C gene and the metabolic syndrome in psychiatric patients.
|
28492956 |
2018 |
|
rs1414334
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Our meta-analyses revealed both a significant positive association between the rs1414334 C allele and olanzapine/clozapine/risperidone-induced metabolic syndrome and a marginally significant positive association between the -697C allele and the induced metabolic syndrome in schizophrenia patients, but no significant association between the -759C/T polymorphism and the induced metabolic syndrome in schizophrenia patients.
|
25152019 |
2014 |
|
rs1414334
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P=0.015).
|
20680028 |
2012 |
|
rs1414334
|
|
|
0.050 |
GeneticVariation |
BEFREE |
The variant rs1414334 C allele was specifically associated with the metabolic syndrome in patients using clozapine (OR, 9.20; 95% CI, 1.95-43.45) or risperidone (OR, 5.35; 95% CI, 1.26-22.83).
|
19142101 |
2009 |
|
rs1414334
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Carriership of the variant alleles of the HTR2C polymorphisms rs518147, rs1414334, and HTR2C:c.1-142948(GT)n was associated with an increased risk of the metabolic syndrome (adjusted odds ratio [OR], 2.62 [95% confidence interval {CI}, 1.00-6.85]; OR, 4.09 [95% CI, 1.41-11.89]; and OR, 3.12 [95% CI, 1.13-8.16]), respectively.
|
17632216 |
2007 |
|
rs518147
|
|
|
0.030 |
GeneticVariation |
BEFREE |
We investigated whether HTR2C:rs518147 (-697G/C), rs12836771 (A/G), LEP: rs7799039 (-2548G/A) and LEPR:rs1137101 (668A/G) are related to MS in psychotic disorder patients treated with atypical antipsychotics.
|
29441581 |
2018 |
|
rs518147
|
|
|
0.030 |
GeneticVariation |
BEFREE |
To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients.
|
25152019 |
2014 |
|
rs518147
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Carriership of the variant alleles of the HTR2C polymorphisms rs518147, rs1414334, and HTR2C:c.1-142948(GT)n was associated with an increased risk of the metabolic syndrome (adjusted odds ratio [OR], 2.62 [95% confidence interval {CI}, 1.00-6.85]; OR, 4.09 [95% CI, 1.41-11.89]; and OR, 3.12 [95% CI, 1.13-8.16]), respectively.
|
17632216 |
2007 |
|
rs12836771
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We investigated whether HTR2C:rs518147 (-697G/C), rs12836771 (A/G), LEP: rs7799039 (-2548G/A) and LEPR:rs1137101 (668A/G) are related to MS in psychotic disorder patients treated with atypical antipsychotics.
|
29441581 |
2018 |